James Berenson, MD
Hematology-Oncology · West Hollywood, CANPI 1124051560
Payments from drug & device makers
Across 1,296 payments — averaging $6456.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$2.6M
- Takeda Pharmaceuticals U.S.A., Inc.$1.4M
- Sanofi$1.1M
- AbbVie$868K
- Karyopharm Therapeutics Inc.$706K
- E.r. Squibb & Sons, L.L.C.$525K
- plus $1.1M from 29 others
Across 6 payments — averaging $20,708 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$104K
- Sanofi$19K
- Amgen$981
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 98 | $2,644,097 |
| Takeda Pharmaceuticals U.S.A., Inc. | 119 | $1,410,491 |
| Sanofi | 219 | $1,117,979 |
| AbbVie | 13 | $868,454 |
| Karyopharm Therapeutics Inc. | 182 | $706,172 |
| E.r. Squibb & Sons, L.L.C. | 141 | $525,255 |
| Bristol Myers Squibb(2 entities) | 62 | $465,484 |
| Amgen | 80 | $385,299 |
| Johnson & Johnson | 188 | $143,408 |
| AMAG Pharmaceuticals, Inc. | 27 | $25,990 |
| Regeneron | 34 | $21,065 |
| GSK | 25 | $19,083 |
| Janssen Research & Development, LLC | 19 | $11,900 |
| Pfizer | 26 | $8,775 |
| Daiichi Sankyo Inc. | 3 | $4,554 |
| Merck | 7 | $3,800 |
| Verastem, Inc. | 1 | $1,725 |
| Aadi Bioscience, Inc. | 2 | $1,700 |
| Janssen Scientific Affairs, LLC | 10 | $531 |
| Sanofi-aventis U.S. LLC | 4 | $297 |
| Sebia Inc | 2 | $153 |
| Regeneron Healthcare Solutions, Inc. | 4 | $146 |
| EUSA Pharma (US) LLC | 2 | $144 |
| Teva Pharmaceuticals USA, Inc. | 5 | $113 |
| Secura Bio, Inc. | 8 | $94 |
| Legend Biotech USA Inc. | 3 | $90 |
| AstraZeneca | 3 | $73 |
| American Regent | 1 | $70 |
| Epizyme, Inc. | 1 | $45 |
| Cardinal Health 108 LLC | 1 | $42 |
| Beigene USA, Inc. | 2 | $40 |
| Gilead | 1 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
How this compares
$8,367,177 in reported general payments places this provider in the 95th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology-oncology in West Hollywood
- Levon QasabianWest Hollywood$415
- Sant ChawlaSanta Monica$10.8M
- Ari BaronSan Francisco$3.1M
- Lee RosenSanta Monica$2.7M
- Ravindranath PatelBakersfield$1.5M
- Ajit ManiamAnaheim$889K
- Veena CharuAnaheim$838K
- Haresh JhangianiFountain Valley$746K
- David KanamoriBakersfield$621K
- Jeffrey WolfSan Francisco$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.